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Objectives: Rapid Virologic Response (RVR) is currently used as the best predictor 
of Sustained Virologic Response (SVR) with dual therapy (DT) in genotype-1 chronic 
hepatitis C (G1-CHC), to optimize the adoption of the triple therapy (TT) with 
direct-acting antivirals (boceprevir: BOC and telaprevir: TVR). Bio-mathematical 
modelling of viral dynamics during DT has potentially higher accuracy than RVR 
in the identification of SVR patients. The objective of this study was to analyse 
the cost-effectiveness profile of a personalized anti-HCV therapy in F0-F2 G1-CHC 
based on a bio-mathematical model (model-guided strategy: MG) rather than on 
the RVR (guideline-guided strategy: GG). MethOds: A deterministic bio-math-
ematical model of the infected cell dynamics was validated in a cohort of 135 
G1-CHC patients treated with DT at the University Hospital in Pisa, Italy. A lifetime 
health economic (HE) model was then developed to compare MG and GG strategies 
in the perspective of the Italian National Health Service. The model was alimented 
with observed data in the validation cohort, clinical variables and economic 
data available in the literature. A 3.5% discount rate was applied to outcomes 
and costs. One-way and probabilistic sensitivity analyses were run. Results: 
The outcomes with MG- and GG-strategy were 19.1-19.4 and 18.9-19.3 quality-
adjusted-life-years (QALY). Total per-patient lifetime costs were € 25,200-€ 26,000 
with MG-strategy and € 28,800-€ 29,900 with GG-strategy. When comparing MG- 
with GG-strategy the former resulted more effective and less costly, being defined 
as dominant. cOnclusiOns: The adoption of a SVR predictive criterion based 
on a bio-mathematical model, has the potential to improve the cost-effectiveness 
of a personalized anti-HCV therapy, allowing a more accurate identification of 
patients who can be effectively treated with DT and reserving high-cost BOC- and 
TVR-based TT for those who really need it.
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Objectives: Pegylated interferon-α plus ribavirin (PR) has been the standard of 
care for Chronic Hepatitis C (CHC). Therapy adding boceprevir (BOC) or telaprevir 
(TVR) to PR in HCV genotype-1 patients has failed to achieve generalized market 
acceptance, in part due to the approval of newer more efficacious and safer options 
like sofosbuvir (SOF), a new pan-genotypic RNA-polymerase inhibitor. Objective: To 
assess the cost-effectiveness of sofosbuvir based therapy for CHC across HCV geno-
types, pretreatment conditions and HIV co-infection in Portugal. MethOds: Costs 
and effectiveness were estimated based on discrete-time Markov-type model for 
CHC evolution accounting for different subpopulations in terms of HCV genotype, 
fibrosis progression, HIV co-infection status and previous treatment experience. 
The model incorporates 13 health states: 5 Metavir score, 2 SVR (with and without 
cirrhosis) and 3 advanced liver disease states (decompensated cirrhosis, hepatocel-
lular carcinoma, liver transplant). Results are expressed in incremental costs per 
life year (LY) and quality-adjusted life year (QALY). Results: Overall sofosbuvir-
containing regimens are expected to result in an increment of 3.49 LY (3.05 QALY) 
after weighting for the different subpopulations assuming Portuguese epidemiol-
ogy. The corresponding weighted incremental cost-effectiveness ratios (ICER) was 
14,649€ /LY (16,720€ /QALY). In the comparison against the BOC and TVR containing 
regimens (genotype-1), ICER of 10,675€ /LY (12,238€ /QALY) and 14,618€ /LY (16,495€ /
QALY) were obtained, respectively. For HIV co-infected and PegIFN eligible/tolerant 
patients, estimated ICER varied between 6,463€ /LY (6,902€ /QALY) and 21,281€ /LY 
(28,245€ /QALY), for G1 and G2, respectively, when comparing against treatment with 
PR. Additionally, in HCV/HIV coinfected patients ineligible/intolerant to PegIFN, the 
comparison against lack-of-therapy resulted in ICER of 15,656€ /LY (17,756€ /QALY) 
and 12,915€ /LY (19,077€ /QALY), for HCV G1 and G3, respectively. cOnclusiOns: 
Sofosbuvir-containing regimens for the treatment of adult CHC patients, irrespec-
tive of HIV co-infection status, are expected to result in significant health gains at 
an incremental cost within the range of European Health Authorities acceptability.
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Objectives: To evaluate the clinical and economic expediency of adding simeprevir 
(SMV) to pegylated-interferon and ribavirin (PR) versus PR only, or triple thera-
pies with PR plus boceprevir (BOC) or telaprevir (TVR) for treatment of genotype 
1 chronic hepatitis C (CHC) virus infection in patients who have failed previous 
therapy with interferon and ribavirin in Russia. MethOds: A Markov model devel-
oped earlier was adapted to the Russian settings. The analysis consists of 2 time 
periods: 1st the antiviral therapy (AVT) phase and 24 week follow-up (0-72 weeks) 
and 2ndthe disease progression of CHC (72 weeks - lifetime). Incidences of disease 
progression health-states (decompensated cirrhosis, hepatocellular carcinoma, liver 
transplant, post-liver transplant and death, associated with high health care costs, 
high mortality rates) based on available published data. Costs and outcomes (life 
years, LY) were analyzed for treatment experienced CHC patients from Russian 
health care system perspective. The incremental cost-effectiveness ratio (ICER) per 
Objectives: To estimate health care costs of alternative therapeutic strategies: 
no treatment versus peginterferon and ribavirin (PR) versus protease inhibi-
tor (PI) boceprevir added to PR for Russian treatment experienced chronic HCV 
patients, who had failure previous treatment, in short- and long-term time hori-
zon. MethOds: An Excel-based model was developed to evaluate costs and 
outcomes of chronic HCV treated with dual therapy with PR and triple therapy 
with boceprevir in combination with PR. Costs for two time periods were ana-
lysed: antiviral therapy costs (0-48 weeks) and disease-progression related costs 
(from 48 weeks to 25 years), depending on the chosen therapy. Antiviral drug costs 
were calculated on the base of registered prices from the list of vital and essential 
drugs. Incidence of compensated and decompensated cirrhosis, hepatocellular 
carcinoma, liver transplant and post-liver transplant in the outcome of chronic 
HCV in long-term period was derived from available published data. Treatment 
costs of liver disease progression events were estimated according to the tariffs 
of the Russian health care system in 2014. Results: Boceprevir +PR compared 
to no treatment strategy and PR therapy was associated with more avoided 
liver-disease progression events at lesser costs, resulting in boceprevir+PR as 
the dominant treatment option in patients with chronic HCV genotype 1 non-
responders to previous treatment in Russia. Additional costs per avoided event of 
liver-disease progression for boceprevir plus PR and dual PR therapy were € 
12,654.26 and € 45,082.82 respectively. cOnclusiOns: Antiviral therapy with 
boceprevir plus PR in comparison with only PR therapy and no treatment strat-
egy is cost effective due to reduced frequency of disease progression events and 
associated costs.
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Objectives: The clinical efficacy of lubiprostone in chronic idiopathic constipa-
tion has been demonstrated in three randomised clinical trials (RCTs). This analy-
sis assesses the cost effectiveness of lubiprostone compared to prucalopride (the 
current standard of care), placebo and immediate referral to secondary care from 
the perspective of the UK National Health Service (NHS). MethOds: A state-
transition model was constructed to represent the treatment pathway for chronic 
idiopathic constipation from an NHS perspective with a 1-year time horizon. The 
model considered treatment continuation rules, at Week 2 for lubiprostone and 
Week 4 for prucalopride. Clinical data were taken from RCTs and an indirect com-
parison with prucalopride. Long-term duration of treatment was estimated by fit-
ting curves to open-label study data. Costs included drug costs, medical resource 
use, and the cost of the pathway including primary and secondary care, obtained 
from published sources. Quality of life was modelled according to whether con-
stipation was resolved or unresolved, with values taken from a large published 
study (n= 1,200). Results: Compared to placebo, lubiprostone delayed referral to 
secondary care and improved quality of life, but resulted in increased costs due to 
treatment, the incremental cost-effectiveness ratio was £2,924. Lubiprostone and 
prucalopride were found to have similar efficacy, with lubiprostone generating an 
additional 0.0014 QALYs in the base case. The cost per day for lubiprostone is lower 
than for prucalopride; leading to lower total costs (£1,596 v £1,655), and meaning 
lubiprostone dominated prucalopride (lower cost and higher QALYs). Probabilistic 
sensitivity analysis showed lubiprostone to have an 84% chance of being the 
most cost-effective treatment at a threshold of £20,000 per QALY. cOnclusiOns: 
Treatment with lubiprostone provides substantial value to both patients and the 
NHS, being highly cost effective compared to placebo and dominant compared to 
the current standard of care.
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Objectives: Constipation-predominant irritable bowel syndrome (IBS-C) affects 
more than 2% of the population carrying a heavy burden in developed countries 
and leading to significant losses in patients’ quality of life. Treatment goals are 
to provide relief of abdominal pain, restore the bowel transit and alleviate associ-
ated symptoms. Linaclotide has been shown to significantly improve abdominal 
and bowel symptoms in two phase III trials being the only EMA approved therapy 
indicated for the treatment of IBS-C. Therefore, this study aimed to perform a 
cost-effectiveness analysis comparing linaclotide with no active treatment for 
the treatment of IBS-C from the Portuguese societal perspective. MethOds: A 
Markov model was developed to simulate the natural course and treatment of the 
disease. Patient-level satisfaction data from linaclotide’s randomised clinical trials 
was used to define 4 health states: ‘Not Satisfied’, ‘Moderately Satisfied’, ‘Satisfied’ 
and ‘Dead’. These data were linked to utility scores based on patients’ responses 
to the EuroQol-5D questionnaire. Transitions between health states were assumed 
to occur every 4 weeks, with probabilities derived from observed efficacy data 
up to 20-weeks. Extrapolation beyond this period was based on last observation 
carried forward data. Effectiveness was measured in quality-adjusted life years 
(QALY). Only direct costs were incorporated. Resource utilization was estimated 
from a literature review. Unit costs came from official Portuguese databases and 
pricing lists. Time horizon was fixed at 10 years. Probabilistic sensitivity analy-
sis was conducted with Monte Carlo simulations. Results: A mean gain of 0.22 
QALY (95%CI: [0.1; 0.35]) was estimated for each patient treated with linaclotide 
versus no treatment. Additionally, linaclotide utilization led to an overall aver-
age cost reduction of 402€ (95%CI: [-1,735; 536]) thus representing a dominant 
option. cOnclusiOns: When compared with no active treatment, linaclotide 
is a cost-saving and more effective therapeutic option for the treatment of IBS-C 
from the Portuguese societal perspective.
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Objectives: Prolonged exposure to CNI-based immunosuppressant therapy (IS) 
in liver transplant (LTx) recipients is associated with long-term complications. 
In the global registration trial H2304, patients receiving everolimus + reduced 
tacrolimus (EVR + reduced TAC) demonstrated non-inferior efficacy and supe-
rior renal function at Month 12 that was sustained at 36 months compared to 
tacrolimus alone (TAC). A peer-reviewed Markov model has been adapted to the 
Italian setting to explore the cost-effectiveness of EVR + reduced TAC compared to 
TAC, in de novo liver-recipients. MethOds: The model estimates long-term out-
comes associated with IS following LTx along two independent pathways: 1. liver-
related (acute rejection, hepatocellular carcinoma, hepatitis C [HCV] recurrence, 
graft loss); 2. kidney-related (chronic kidney disease, dialysis, renal transplanta-
tion) and death. All patients, stratified by liver diagnosis, entered the model at time 
of LTx and followed both pathways, allowing for multiple combinations of liver 
and kidney health states. The lifetime model used an annual cycle length 
except for the 1styear post LTx (quarterly). Efficacy and safety of IS strategies 
were assessed through the risk of acute rejection, change in renal function, HCV 
fibrosis progression and frequency of adverse events. Utilities and costs were 
assigned to each renal and liver state. Subgroup and sensitivity analyses were 
performed. Results: With a mean life expectancy of 18 years, the model predicts 
patients treated with EVR + reduced TAC gain on average 1.84 years of life and 1.55 
QALYs vs. TAC. The risk of acute rejection was reduced by 20%. The incremental 
cost of EVR + TAC was € 38,884 per life year gained and € 46,103 per QALY gained 
vs. TAC. cOnclusiOns: This model shows a strategy of EVR + reduced TAC post- 
LTx improves survival and quality of life. Higher treatment costs are offset by 
slower progression of renal deterioration predicted in the first 10 years and fewer 
lifetime liver complications.
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Objectives: Nonalcoholic fatty liver disease (NAFLD) is the most common liver 
condition in Western countries. To date, no studies have examined the cost-
effectiveness of screening for nonalcoholic steatohepatitis (NASH), its advanced 
form. MethOds: We performed a cost-utility analysis of annual non-invasive 
screening strategies using a third-party payer perspective in a general population 
and compared it to screening in a high-risk obese or diabetic population. Screening 
algorithms involved well-studied non-invasive techniques including NAFLD fibro-
sis score, ultrasound transient elastography (TE), and ultrasound acoustic radiation 
force impulse (ARFI) imaging for detecting advanced fibrosis (≥ F3); and plasma 
cytokeratin-18 for NASH detection. Liver biopsy and magnetic resonance elas-
tography (MRE) were compared as confirmation methods. Model uncertainties 
were tested using sensitivity analyses. Canadian dollar costs were adjusted for 
inflation and discounted at 5%. Incremental cost-effectiveness ratio (ICER) of 
$C50,000 per quality-adjusted life year (QALY) or less was considered cost-effec-
tive. Results: Compared with no screening, screening with NAFLD fibrosis score/
TE/CK-18 algorithm with MRE as confirmation for advanced fibrosis had an ICER 
of $C26,143 per QALY gained. Screening in high-risk obese or diabetic populations 
was more cost-effective, with an ICER of $C9,051 and $C7,991 per QALY gained 
respectively. Screening algorithms with liver biopsy confirmation were not found 
to be cost-effective. Sensitivity analyses revealed that the screening starting age, 
the annual transition probability from simple steatosis to NASH, and the cost of 
a TE exam had the most impact on the results. cOnclusiOns: Our model sug-
gests that annual NASH screening in high-risk obese or diabetic populations can 
be cost-effective.
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Objectives: Sofosbuvir in combination with ribavirin (SOF/RBV) is a novel treat-
ment able to suppress HCV viremia when applied to HCV patients listed for 
transplant, preventing HCV recurrence. Aim of this study was to assess the cost-
effectiveness of this regimen in HCV patients listed for transplant for cirrhosis (HCV-
cirrhosis) or for hepatocellular carcinoma (HCV-HCC). MethOds: a semi-Markov 
model was developed. The model simulates the progression of HCV-cirrhosis or 
HCV-HCC patients from the time of listing until death considering the risk of HCV 
recurrence post-transplant. The model compared 2 different strategies: 1) SOF/RBV 
up to a maximum of 24 weeks or until OLT if performed before the 24th week, 2) 
No antiviral treatment. The model estimated the costs related to the treatment 
with SOF/RBV, the costs associated to each health state, the life-years (LYSs), the 
quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio 
(ICER) expressed as € per QALY gained. The analysis was performed from the Italian 
National Health System perspective with a lifetime time horizon and one-month 
Markov cycles. Future costs and clinical benefits, expressed as QALYs, were dis-
counted at 3% per year. Results: in the base-case analysis the ICER for 24 weeks 
of SOF/RBVR was € 30,518 per QALY gained in HCV-cirrhosis patients and € 41,610 
in HCV-HCC patients. The reliability of our results was confirmed by the one way 
sensitivity-analysis and by the cost-effectiveness acceptability curve. Further, SOF/
RBV cost-effectiveness was clearly sensitive to the duration of treatment; assum-
ing 12 weeks SOF/RBV treatment duration, the ICER decreased to € 19,317 in HCV-
Cirrhosis and € 29,540 in HCV-HCC. cOnclusiOns: our study shows that treating 
patients with HCV-cirrhosis or HCV-HCC listed for transplant with SOF/RBV is cost-
effective and may become the new standard of care for these patients. However a 
well-defined prospective study is needed to confirm the value of the parameters 
assumed in the model and the results.
LY was calculated. Sensitivity analyses were performed. Results: Model results for 
treatment-experienced patients show that SMV is the dominant treatment com-
pared to TVR+PR and BOC+PR therapies as more total LYs are saved and less costs 
accrued. ICER of SMV+PR vs PR was € 22,967 per LY. Results were robust in sensitivity 
analyses. cOnclusiOns: SMV + PR is cost-effective compared to dual PR-therapy 
and appears the dominant strategy compared to other PI (telaprevir, boceprevir) for 
CHC treatment-experienced patients in Russia.
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Objectives: Studies based on the data of clinical trials have proved that the triple 
therapy for hepatitis C is cost effective. This study we assessed the cost-effective-
ness of triple therapy in treatment of Chronic Hepatitis C with Severe Fibrosis under 
“real-life” conditions. MethOds: The analysis was conducted from the data included 
in the prospective, multicentre, Spanish registry that includes patients with HCV-
genotype-1 infection, who had severe fibrosis and were treated with triple therapy 
(peginterferon alfa-2a or 2b, ribavirin, and boceprevir). The cost effectiveness analysis 
of antiviral treatment includes the costs of antiviral treatment, of concomitant treat-
ments and costs in relation to health care resources (in relation to clinical practice 
and the adverse events). Results: 170 patients were included. 68.2% male, mean 
age of 53 (29-76) years. 80% had received prior treatment. 36.5% of patients reported 
at least one SAEs. The overall percentage of patients with SVRw12 was 46.5%. The 
cost of triple therapy represented a total of 4,916,652.84€ , the pharmacological cost 
(triple therapy+concomitant treatment) involved a total cost of 5,161,168.98€ . The 
consumption of health resources generated an additional cost of 240,000 € , which is 
about 1,500€ /patient. The total cost per patient cured was 70,262€ . This cost varies 
greatly based on different baseline characteristics of the patients, with significant 
differences in patients with albumin < 3.5, 120,597€ ; prior null response 120,727€ and 
platelets < 90,000,104,464€ . cOnclusiOns: The current scenario of the hepatitis C 
treatment is changing. Triple therapy is more costly for patients with severe fibrosis 
and predictors of poor response. However, keeping in mind that the timeframe for the 
release of IFN-free regimens remains uncertain and considered that the actual access 
to the new DAA in the real world setting could be delayed, boceprevir could remain 
as an option for patients with intact liver function and a high unmet medical need, 
regardless of the degree of liver fibrosis, in locations where a delay in the access to 
the newer therapies is foreseen and hepatic transplant would not be readily available.
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Objectives: The aim of this study is to compare the cost effectiveness of oral anti-
viral treatment strategies in CHB for Turkey using lamuvidine, telbuvidine, entecavir, 
and tenofovir as medications. MethOds: The analysis was conducted using Markov 
model. Inadequate response or resistance after receiving 12 months of the treatment 
with entecavir and telbivudine were compared to the results found from switching 
from entecavir to tenofovir or from switching from telbuvidine to tenofovir. In addi-
tional, inadequate response or resistance after receiving 6 months of the treatment 
for lamivudine was compared to the results found from switching from lamivudine 
to tenofovir. The model duration was constructed to evaluate a treatment strategy 
duration of 40 years. Years of Potential Life Lost (YPLL) was used as the health 
outcome. An incremental cost-effectiveness ratio (ICER) analysis of the results was 
conducted. Results: In a life time period, the lowest YPLL and the cost of treatment 
were calculated for the NS. Tenofovir treatment with 0.54 years and 37,213.75 TL. 
Depending on the results, the lowest YPLL and the cost of treatment were served 
by NS. Tenofovir treatment with 2.06 years and 276,468.45 TL. The highest YPLL and 
the cost of treatment were calculated for the NS. The ICER analysis found that all 
treatment strategies were dominated by NS. Tenofovir and S. Entecavir. Only these 
two treatment strategies were found to be cost-effective. cOnclusiOns: The cost 
of providing 40 years of treatment for patients with CHB, if reimbursement agen-
cies includes Tenofovir and Entecavir as part of the first line treatment strategy for 
CHB, it can be expected that this approach would result in a positive contribution 
to the health budget in Turkey.
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